Lifordi Immunotherapeutics, Inc.
Biotechnology company developing targeted antibody-drug conjugate (ADC) therapies that deliver immunomodulatory payloads selectively to immune cells for treatment of autoimmune and inflammatory diseases. Programs have demonstrated preclinical efficacy and safety and the lead candidate has entered Phase 1 clinical evaluation. The team combines translational immunology, clinical development, CMC and manufacturing expertise.
Industries
Nr. of Employees
small (1-50)
Lifordi Immunotherapeutics, Inc.
Products
Lead immunomodulatory ADC clinical candidate (glucocorticoid payload)
A targeted antibody‑drug conjugate designed to selectively deliver a glucocorticoid payload to immune cells to achieve sustained anti‑inflammatory effects while limiting systemic exposure and toxicity; advanced into Phase 1 clinical evaluation for rheumatoid arthritis.
Lead immunomodulatory ADC clinical candidate (glucocorticoid payload)
A targeted antibody‑drug conjugate designed to selectively deliver a glucocorticoid payload to immune cells to achieve sustained anti‑inflammatory effects while limiting systemic exposure and toxicity; advanced into Phase 1 clinical evaluation for rheumatoid arthritis.
Expertise Areas
- Targeted antibody‑drug conjugates (ADCs) for immunology
- Preclinical efficacy and safety assessment
- Translational medicine and early clinical development
- CMC and GMP process development for biologics
Key Technologies
- Antibody‑drug conjugates (ADCs)
- Targeted delivery to immune cell surface receptors
- Small molecule payload conjugation
- Nucleic acid payload delivery via targeted conjugates
News & Updates
Poster describing selective delivery of a glucocorticoid payload to immune cells with sustained anti‑inflammatory effects in non‑human primates.
Preclinical data presentation on an immune‑targeted glucocorticoid ADC for autoimmune and inflammatory diseases.
Announcement of Phase 1 clinical trial initiation for the lead glucocorticoid ADC candidate in rheumatoid arthritis.
Profile article describing the company approach of applying antibody‑drug conjugate strategies to autoimmune disease.
Named winner of Endpoints 11 as a developer of ADCs for autoimmune and inflammatory diseases.
Poster describing selective delivery of a glucocorticoid payload to immune cells with sustained anti‑inflammatory effects in non‑human primates.
Preclinical data presentation on an immune‑targeted glucocorticoid ADC for autoimmune and inflammatory diseases.
Announcement of Phase 1 clinical trial initiation for the lead glucocorticoid ADC candidate in rheumatoid arthritis.
Profile article describing the company approach of applying antibody‑drug conjugate strategies to autoimmune disease.
Named winner of Endpoints 11 as a developer of ADCs for autoimmune and inflammatory diseases.